Oct 29, 2015 7:00 am EDT NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015
Oct 28, 2015 7:08 pm EDT NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services
Sep 23, 2015 7:00 am EDT NeoGenomics Launches New NeoSITE™ Cervical FISH Assay for Evaluation of Abnormal Pap Tests
Sep 2, 2015 7:00 am EDT NeoGenomics Enters into National Agreement with Premier, Inc. to Offer Cancer Genetics Testing Services to 3,600 Hospitals
